feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Brain Cancer Drug Given Years Too Long, Ruining Lives

Brain Cancer Drug Given Years Too Long, Ruining Lives

19 Nov, 2025

•

Summary

  • Patients received excessive chemotherapy drugs for two decades.
  • Overdosing left patients housebound with severe side effects.
  • Legal action is being prepared against the hospital trust.
Brain Cancer Drug Given Years Too Long, Ruining Lives

Dozens of patients allege their lives were severely impacted by prolonged and unnecessary chemotherapy treatments administered over two decades at the University Hospitals Coventry and Warwickshire NHS Trust. Gayle Bodinnar, diagnosed with a brain tumor, received over 150 cycles of the drug temozolomide, significantly exceeding the recommended six-month NHS protocol.

This excessive treatment resulted in debilitating side effects for Ms. Bodinnar, including chronic fatigue, memory issues, and becoming housebound for life. Many other patients reported similar consequences, such as extreme exhaustion, sickness, seizures, and secondary cancers, with some facing ruined careers.

Legal action is now being prepared against the trust, with patients demanding an independent investigation into the treatments provided. Lawyers are calling for a review dating back to 2006, encompassing multiple clinicians and pharmacists involved in the repeated prescribing of the drug.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Temozolomide is a powerful chemotherapy drug for brain tumors. Patients allege it was given for years beyond the recommended six months without proper consent or clinical trial documentation.
Patients reported devastating side effects including extreme fatigue, confusion, memory loss, sickness, seizures, and in some cases, secondary cancers, leading to a severely diminished quality of life.
Yes, over 30 patients are preparing legal action against the trust, seeking answers and accountability for the prolonged and allegedly unnecessary chemotherapy treatments.

Read more news on

Healthside-arrow
trending

Salesforce lays off 1000

trending

India US trade tariffs slashed

trending

Margot Robbie's Wuthering Heights panned

trending

CBSE board exams: key details

trending

Jana Nayagan movie court case

trending

Dhakshineswar Suresh Davis Cup hero

trending

Deepika Padukone wears Gaurav Gupta

trending

NZ vs UAE match prediction

trending

iPhone 17 Croma Valentine's sale

You may also like

Rugby MP Demands Doctor-Led Urgent Care Upgrade

1 hour ago

article image

8 Years of Wrong Chemo: Man's Life Ruined

30 Jan • 124 reads

article image

Hospital Critical Incident Stood Down After Severe Pressure

24 Jan • 100 reads

article image

NHS Trust Declares Critical Incident Amidst A&E Overload

15 Jan • 189 reads

article image

Coventry Hospital Boosts Waiting Room Seats by Over 50%

31 Dec, 2025 • 202 reads

article image